MSB 1.56% 94.5¢ mesoblast limited

Ann: COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT, page-40

  1. 15,618 Posts.
    lightbulb Created with Sketch. 5701
    Sydney's situation would surely enable treatment by Remestemcel-L if the FDA issued an EUA .... other COVID-19 treatments and COVID-19 vaccines were given the green light by the TGA here once FDA issued either an EUA or Approval but again everyone (NIH, FDA, MSB, NVS etc) take your time ?

    This graph from NSW Health shows ICU not ventilated and ICU ventilated numbers are on the rise and of course we know deaths have started to occur this past week as well ... disappointing that a treatment developed by an Australian company that is showing great results each time new data is released can only be accessed in Australia through the TGA Special Access Scheme - seems a little ridiculous ?

    upload_2021-7-19_11-30-50.png
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
94.5¢
Change
-0.015(1.56%)
Mkt cap ! $1.090B
Open High Low Value Volume
95.5¢ 97.0¢ 94.0¢ $626.4K 658.4K

Buyers (Bids)

No. Vol. Price($)
18 24294 94.5¢
 

Sellers (Offers)

Price($) Vol. No.
95.0¢ 47421 20
View Market Depth
Last trade - 12.16pm 13/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.